TLP
IRLA

Tri Locum Partners’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Tri Locum Partners’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-111
Closed -$14K – 80
2022
Q4 		$14K Buy
+111
New +$18.6K 0.01% 69

Other funds holding IRLA

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tri Locum Partners's IRLA Position: Q1 2023 in Review

Tri Locum Partners sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2023, closing a stake of 111 shares — an estimated $14K sold.

Tri Locum Partners first reported a position in IRLA in Q4 2022 and held it in 1 quarter. The position peaked at $14K in Q4 2022. 42 funds tracked by Wall St. Rank hold IRLA as of Q1 2023.

  • Tri Locum Partners reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 111 IRulya Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $14K.
  • Tri Locum Partners first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Tri Locum Partners's IRulya Therapeutics Inc. Common Stock position peaked at $14K in Q4 2022.
  • 42 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.